In the ER + breast cancer context, ELF3 can repress the transcriptional function of ERα66 [71], similar to the role of its family member ELF5, which can suppress ERα66 and its downstream targets, thus mediating tamoxifen resistance in luminal breast cancer cells [72]. This evidence concerns the gene ELF5 and breast cancer.